Prof. Dr. Klaus Langer

Prof. Dr. Klaus Langer

Institutsdirektor

Apotheker

Institut für Pharmazeutische Technologie und Biopharmazie
Corrensstr. 48
D - 48149 Münster

Raum C.110.159

Tel.: +49 (0)251 - 8339860
Fax: +49 (0)251 - 8339308

E-Mail: k.langer [at] uni-muenster [dot] de

  • Forschungsschwerpunkte

    • Drug Targeting mittels Nanotechnologie
    • Zielspezifische Tumortherapie
    • Formulierung von Arzneistoffen

  • Vita

    Akademische Ausbildung

    Habilitation und Venia legendi im Fach "Pharmazeutische Technologie", Goethe-Universität Frankfurt
    -
    Promotionsarbeit im Fach "Pharmazeutische Technologie", Johann Wolfgang Goethe-Universität Frankfurt

    Beruflicher Werdegang

    seit
    Universitätsprofessor für Pharmazeutische Technologie, WWU Münster
    -
    Wissenschaftlicher Mitarbeiter am Institut für Pharmazeutische Technologie, Goethe-Universität Frankfurt
    Gastprofessur für Pharmazeutische Technologie, Karl-Franzens-Universität Graz
    -
    Pharmazeutisches Praktikum in einer Apotheke und bei der STADA Arzneimittel AG

    Preise

    PHOENIX Pharmazie Wissenschaftspreis 2016 - PHOENIX group
    Lehrpreis der WWU 2015 - Jury für die Vergabe des Lehrpreises der WWU
    Preis des Fachbereichs Biochemie, Chemie und Pharmazie für exzellente Lehre - Goethe-Universität, Frankfurt
    Adolf Messer Stiftungspreis 2003 - Adolf Messer Stiftung

  • Projekte

    Laufend
    • Entwicklung einer Arzneiform zur TG-1-Enzymsubstitution der lamallären Ichthyose ( - )
      Drittmittel: United for Fighting Ichthyosis - Amici per la Pelle
    • Stabilisierung von nanopartikulären pharmazeutischen Wirkstoffen durch humanes Serumalbumin (HSA) ( - )
      Drittmittel: INVITE GmbH
    • Transglutaminase 1-Liposomen - Forschungsarbeiten auf dem Gebiet der lamellären Ichthyose ( - )
      Drittmittel: Leibniz-Forschungsinstitut für Molekulare Pharmakologie
    • PharMSchool ( - )
      Drittmittel: Universitätsgesellschaft Münster e.V., Deutsche Pharmazeutische Gesellschaft e.V., Rottendorf Stiftung
    • Selbstbeschleunigte "Drug Delivery"-Systeme als Basis von Polycarbonatcopolymeren ( - )
      Drittmittel: DFG - Sachbeihilfe/Einzelförderung | Förderkennzeichen: LA 1165/5-1
    • Patientenrelevanz generischer Substitution am Beispiel von L-Dopa ( - )
      Drittmittel: Apothekerstiftung Westfalen-Lippe | Förderkennzeichen: Wa/mie
    • EXC 1003 B1 - Ausbildung und Eigenschaften von epithelialen und endothelialen Zellbarrieren ( - )
      Drittmittel: DFG - Exzellenzcluster | Förderkennzeichen: EXC1003/1
    • Auftragsanalytik (REM, DSC, ...) für den Bereich der Arzneimittelherstellung ( - )
      Drittmittel: Rottendorf Pharma GmbH
    • Verbundprojekt: Zielgesteuerte BioTransporter oral applizierter Photosensibilisatoren zur photodynamischen Therapie gastrointestinaler Carcinome (GITCare) - Teilvorhaben: Nanostrukturierte Trägersysteme und deren biologische Bewertung ( - )
      Drittmittel: Bundesministerium für Bildung und Forschung | Förderkennzeichen: 13N13423
    • Rezepturfit - Validierung von Rezepturprozessen ( - )
      Drittmittel: Apothekerstiftung Westfalen-Lippe
    Abgeschlossen
    • PharMSchool-Symposium ()
      Drittmittel: Sonstige Mittelgeber
    • BioTraP for CCC - Biokonjugate zur peroralen Anwendung für den Transport von Problemarzneistoffen zur Behandlung des Cholangiozellulären Karzinoms ( - )
      Drittmittel: Bundesministerium für Bildung und Forschung | Förderkennzeichen: 13N11390
    • NanoGene - Stem cell generation and manipulation by nanoparticle mediated gene transfer for the safe clinical application of gene-modified cells ( - )
      Drittmittel: Bundesministerium für Bildung und Forschung | Förderkennzeichen: 13N1I539
    • NanoBrain - ERA-NET Neuron NanoBrain ( - )
      Drittmittel: Sonstige Mittelgeber
    • Schaltbare Nanopartikel als Wirkstoffträger ( - )
      Eigenmittel
    • NanoCancer - Development of cell type specific drug carrier systems for cancer therapy ( - )
      Eigenmittel
    • NanoDrug - Nanopartikuläre Arzneistoffsysteme für die gezielte Tumortherapie ( - )
      Eigenmittel

  • Publikationen

    Aufsätze (Zeitschriften)

    • Barth C., Spreen H., Mulac D., Keuter L., Behrens M., Humpf H.-U., Langer K. . ‘Spacer length and serum protein adsorption affect active targeting of trastuzumab-modified nanoparticles.’ Biomater. Biosyst. 5: 100032.
    • Schoppa T., Jung D., Rust T., Mulac D., Kuckling D., Langer K. . ‘Light-responsive nanoparticles based on a novel nitropiperonal derived polyester as drug delivery systems for photosensitizers in PDT.’ Int. J. Pharm. 597: 120326.
    • Hester S., Ferenz K.B., Eitner S., Langer K. . ‘Development of a lyophilization process for long term storage of albumin based perfluorodecalin filled artificial oxygen carriers.’ Pharmaceutics 13: 584.
    • Jung D., Rust T., Völlmecke K., Schoppa T., Langer K., Kuckling D. . ‘Backbone vs. side-chain: Two light-degradable polyurethanes based on 6-nitropiperonal.’ Polym. Chem. 12: 4565-4575.
    • Spreen H., Behrens M., Mulac D., Humpf H., Langer K. . ‘Identification of main influencing factors on the protein corona composition of PLGA and PLA nanoparticles.’ Eur. J. PHarm. Biopharm. 163: 212-222.
    • Rust T., Jung D., Hoppe A., Schoppa T., Langer K., Kuckling D. . ‘Backbone-degradable (co-)polymers for light-triggered drug delivery.’ ACS Appl. Polym. Mater. 2021: 3831-3842.
    • Wünsch A., Mulac D., Langer K. . ‘Lecithin coating as universal stabilization and functionalization strategy for nanosized drug carriers to overcome the blood-brain barrier.’ Int. J. Pharm. 593: 120146.
    • Langer K. . „mRNA- und DNA-Impfstoffe – Nanotechnologie der Covid-19-Vakzinen.“ Pharm. Ztg. 166: 1024-1031.
    • Sahnen F., Kamps J.P., Langer K. . ‘Conversion of indomethacin nanosuspensions into solid dosage forms via fluid bed granulation and compaction.’ Eur. J. Pharm. Biopharm. 154: 89-97.
    • Wünsch A., Mulac D., Langer K. . ‘Lipoprotein imitating nanoparticles: Lecithin coating binds ApoE and mediates non-lysosomal uptake leading to transcytosis over the blood-brain barrier.’ Int. J. Pharm. 589: 119821.
    • Stein N.C., Mulac D., Fabian J., Herrmann F.C., Langer K. . ‘Nanoparticle albumin-bound mTHPC for photodynamic therapy: Preparation and comprehensive characterization of a promising drug delivery system.’ Int. J. Pharm. 582: 119347.
    • Mecate-Zambrano A., Sukumar S., Seebohm G., Ciminski K., Schreiber A., Anhlan D., Greune L., Wixler L., Grothe S., Stein N.C., Schmidt M.A., Langer K., Schwemmle M., Shi T., Ludwig S., Boergeling Y. . ‘Discrete spatio-temporal regulation of tyrosine phosphorylation directs influenza A virus M1 protein towards its function in virion assembly.’ PLoS Pathogenes 16: e1008775.
    • Langer K. . „Adjuvanzien im Europäischen Arzneibuch – Adjuvants in the European Pharmacopoeia.“ Pharmakon 8: 351-356.
    • Keuth J., Nitschke Y., Mulac D., Riehemann K., Rutsch F., Langer K. . ‘Reversion of arterial calcification by elastin-targeted DTPA-HSA nanoparticles.’ Eur. J. Pharm. Biopharm. 150: 108-119.
    • Weitzel J., Langer K., Erzkamp S., Rose O. . ‘Effects of generic exchange of solid oral dosage forms in neurological disorders: A systematic review.’ Int. J. Clin. Pharm. 42: 393-417.
    • Sun J., Anderski J., Picker M.-T. Langer K., Kuckling D. . ‘Preparation of light-responsive aliphatic polycarbonate via versatile polycondensation for controlled degradation.’ Macromol. Chem. Phys. 220: 1800539.
    • Anderski J., Mahlert L., Sun J., Birnbaum W., Mulac D., Schreiber S., Herrmann F., Kuckling D., Langer K. . ‘Light-responsive nanoparticles based on new polycarbonates as innovative drug delivery systems for photosensitizers in PDT.’ International Journal of Pharmaceutics 557: 182-191.
    • Mahlert L., Anderski J., Mulac D., Langer K. . ‘The impact of gastrointestinal mucus – new in vitro evaluation of promising mucus-penetrating PLGA-NP for photodynamic therapy in treatment of intestinal cancer.’ Eur. J. Pharm. Sci. 133: 28-39.
    • Partikel K., Korte R., Mulac D., Humpf H.-U., Langer K. . ‘Serum type and concentration both affecting the protein corona composition of PLGA nanoparticles.’ Beilstein J. Nanotechnol. 10: 1002-1015.
    • Onafuye H., Pieper S., Mulac D., Cinatl jr. J., Wass M.N., Langer K., Michaelis M. . ‘Doxorubicin-loaded human serum albumin nanoparticles overcome transporter-mediated drug resistance.’ Beilstein J. Nanotechnol. 10: 1707-1715.
    • Partikel K., Korte R., Stein N.C., Mulac D., Herrmann F.C., Humpf H.-U., Langer K. . ‘Effect of nanoparticle size and PEGylation on the protein corona of PLGA nanoparticles.’ Eur. J. Pharm. Biopharm. 2019: 70-80.
    • Mahlert L., Anderski J., Schoppa T., Mulac D., Sun J., Kuckling D., Langer K. . ‘In vitro evaluation of innovative light-responsive nanoparticles for controlled drug release in intestinal PDT.’ Int. J. Pharm. 565: 199-208.
    • Kimani N.M., Backhaus S., Matasyoh J.C., Kaiser M., Herrmann F.C., Schmidt T.J., Langer K. . ‘Preparation of sesquiterpene lactone loaded - PLA nanoparticles and evaluation of their antitrypanosomal activity.’ Molecules 24: 2110.
    • Sun J., Jung D., Schoppa T., Anderski J., Picker M.-T., Ren Y., Mulac D., Stein N., Langer K., Kuckling D. . ‘Light-responsive serinol-based poylcarbonate and polyester as degradable scaffolds.’ ACS Applied Bio Materials 2: 3038-3051.
    • Pieper S., Onafuye H., Mulac D., Cinatl J., Wass M.N. Michaelis M., Langer K. . ‘Incorporation of doxorubicin in different polymer nanoparticles and their anti-cancer activity.’ Beilstein J. Nanotechnol. 10: 2062-2072.
    • Raudszus B., Mulac D., Langer K. . ‘A new preparation strategy for surface modified PLA nanoparticles to enhance uptake by endothelial cells.’ International Journal of Pharmaceutics 536, Nr. 1: 211-221. doi: 10.1016/j.ijpharm.2017.11.047.
    • Franz J., Grünebaum J., Schäfer M., Mulac D., Rehfeldt F., Langer K., Kramer A., Riethmüller C. . ‘Rhombic organization of microvilli domains found in a cell model of the human intestine.’ PLoS ONE 13, Nr. 1. doi: 10.1371/journal.pone.0189970.
    • Anderski J., Mahlert L., Mulac D., Langer K. . ‘Mucus-penetrating nanoparticles: Promising drug delivery systems for the photodynamic therapy of intestinal cancer.’ European Journal of Pharmaceutics and Biopharmaceutics 129: 1-9.
    • Gossmann R., Spek S., Langer K., Mulac D. . ‘Didodecyldimethylammonium bromide (DMAB) stabilized poly(lactic-co-glycolic acid) (PLGA) nanoparticles: Uptake and cytotoxic potential in Caco-2 cells.’ Journal of Drug Delivery Science and Technology 43, Nr. null: 430-438. doi: 10.1016/j.jddst.2017.11.002.
    • Sun J., Birnbaum W., Anderski J., Picker M.-T., Mulac D., Langer K., Kuckling D. . ‘Use of light-degradable aliphatic polycarbonate nanoparticles as drug carrier for photosensitizer.’ Biomacromolecules 19: 4677-4690.
    • Horster L., Bernhardt A., Kiehm K., Langer K. . ‘Conversion of PLGA nanoparticle suspensions into solid dosage forms via fluid bed granulation and tableting.’ European Journal Pharmaceutics Biopharmaceutics 134: 77-87.
    • Mesken J., Iltsche A., Mulac D., Langer K. . ‘Modifying plasmid-loaded HSA-nanoparticles with cell penetrating peptides −cellular uptake and enhanced gene delivery.’ International Journal of Pharmaceutics 522: 198-209. doi: 10.1016/j.ijpharm.2017.03.006.
    • Fahrländer E., Schelhaas S., Jacobs A., Langer K. . ‘PEGylated human serum albumin (HSA) nanoparticles: Preparation, characterization and quantification of the PEGylation extent.’ Nanotechnology 26, Nr. 14: 145103. doi: 10.1088/0957-4484/26/14/145103.
    • Lappe S., Mulac D., Langer K. . ‘Polymeric nanoparticles – Influence of the glass transition temperature on drug release.’ International Journal of Pharmaceutics 517, Nr. null: 338-347. doi: 10.1016/j.ijpharm.2016.12.025.
    • Gonnissen D., Qu Y., Langer K., Öztürk C., Zhao Y., Chen C., Seebohm G., Düfer M., Fuchs H., Galla H., Riehemann K. . ‘Comparison of cellular effects of starch-coated SPIONs and poly(Lactic-co-glycolic acid) matrix nanoparticles on human monocytes.’ International Journal of Nanomedicine 11, Nr. null: 5221-5236. doi: 10.2147/IJN.S106540.
    • Niehoff A., Grünebaum J., Moosmann A., Mulac D., Söbbing J., Niehaus R., Buchholz R., Kröger S., Wiehe A., Wagner S., Sperling M., von Briesen H., Langer K., Karst U. . ‘Quantitative bioimaging of platinum group elements in tumor spheroids.’ Analytica Chimica Acta 938, Nr. null: 106-113. doi: 10.1016/j.aca.2016.07.021.
    • John C, Herz T, Boos J, Langer K, Hempel G. . ‘Asymmetrical flow field-flow fractionation for the analysis of PEG-asparaginase.’ Talanta 146: 335-339. doi: 10.1016/j.talanta.2015.08.028.
    • Lüdeker D., Gossmann R., Langer K., Brunklaus G. . ‘Crystal Engineering of Pharmaceutical Co-crystals: "nMR Crystallography" of Niclosamide Co-crystals.’ Crystal Growth and Design 16, Nr. 6: 3087-3100. doi: 10.1021/acs.cgd.5b01619.
    • Grünebaum J., Söbbing J., Mulac D., Langer K. . ‘Nanoparticulate carriers for photodynamic therapy of cholangiocarcinoma: In vitro comparison of various polymer-based nanoparticles.’ International Journal of Pharmaceutics 496, Nr. 2: 942-952. doi: 10.1016/j.ijpharm.2015.10.023.
    • Gossmann R., Langer K., Mulac D. . ‘New perspective in the formulation and characterization of didodecyldimethylammonium bromide (DMAB) stabilized poly(lactic-co-glycolic acid) (PLGA) nanoparticles.’ PLoS ONE 10, Nr. 7. doi: 10.1371/journal.pone.0127532.
    • Afrimzon E., Zurgil N., Sobolev M., Shafran Y., Langer K., Zlatev I., Wronski R., Windisch M., von Briesen H., Schmidt R., Pietrzik C., Deutsch M. . ‘Detection and analysis of human serum albumin nanoparticles within phagocytic cells at the resolution of individual live cell or single 3D multicellular spheroid.’ Journal of Nanoparticle Research 17, Nr. 12: 1-14. doi: 10.1007/s11051-015-3306-9.
    • John C., Herz T., Boos J., Langer K., Hempel G. . ‘A novel asymmetrical flow field-flow fractionation for the analysis of PEG asparaginase.’ Talanta 146: 335-339.
    • Look J., Wilhelm N., von Briesen H., Noske N., Günther C., Langer K., Gorjup E. . ‘Ligand-modified human serum albumin nanoparticles for targeted gene delivery.’ Mol. Pharm. 12: 3202-3213.
    • Spek S., Häuser M., Schäfer M.M., Langer K. . ‘Characterisation of PEGylated PLGA nanoparticles comparing the nanoparticle bulk to the particle surface using UV/Vis spectroscopy, SEC, 1H-NMR spectroscopy, and X-ray photoelectron spectroscopy.’ Appl. Surf. Sci. 347.
    • Plöger M., Sendker J., Langer K., Schmidt T.J. . ‘Covalent modification of human serum albumin by the natural sesquiterpene lactone parthenolide.’ Molecules 20.
    • Michaelis M., Agha B., Rothweiler F., Löschmann N., Voges Y., Mittelbronn M., Starzetz T., Harter P.N., Abhari B.A., Fulda S., Westermann F., Riecken K., Spek S., Langer K., Wiese M., Dirks W.G., Zehner R., Cinatl J., Wass M.N., Cinatl jr. J. . ‘Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen.’ Sci. Rep. 5.
    • Borgognoni C., Mormann M., Qu Y., Schäfer M., Langer K., Öztürk C., Wagner S., Chen C., Zhao Y., Fuchs H., Riehemann K. . ‘Reaction of human macrophages on protein corona covered TiO2 nanoparticles.’ Nanomedicine: Nanotechnology, Biology, and Medicine 11, Nr. 2: 275-282. doi: 10.1016/j.nano.2014.10.001.
    • Langer K. . „2nd Pharm School Symposium: Networked study in Münster.“ Pharmazeutische Zeitung 160, Nr. 6.
    • Gossmann R., Fahrländer E., Hummel M., Mulac D., Brockmeyer J., Langer K. . ‘Comparative examination of adsorption of serum proteins on HSA- and PLGA-based nanoparticles using SDS-PAGE and LC-MS.’ European Journal of Pharmaceutics and Biopharmaceutics 93, Nr. null: 80-87. doi: 10.1016/j.ejpb.2015.03.021.
    • Martínez Vera N.P., Schmidt R., Langer K., Zlatev I., Wronski R., Auer E., Havas D., Windisch M., von Briesen H., Wagner S., Stab J., Deutsch M., Pietrzik C., Fazekas F., Ropele S. . ‘Tracking of magnetite labeled nanoparticles in the rat brain using MRI.’ PloS one 9, Nr. 3: e92068. doi: 10.1371/journal.pone.0092068.
    • John C., Langer K. . ‘Asymmetrical flow field-flow fractionation for human serum albumin based nanoparticle characterisation and a deeper insight into particle formation processes.’ Journal of chromatography A 1346: 97-106. doi: 10.1016/j.chroma.2014.04.048.
    • Langer K. . „Medicine-related problems in practice: Tablet splitting - (no) a problem? | Arzneimittelbezogene Probleme in der Praxis: Tablettenteilung - (k)ein Problem?“ PZ Prisma 21, Nr. 2: 75-81.
    • Engel A., Ploger M., Mulac D., Langer K. . ‘Asymmetric flow field-flow fractionation (AF4) for the quantification of nanoparticle release from tablets during dissolution testing.’ International Journal of Pharmaceutics 461, Nr. 1: 137-144. doi: 10.1016/j.ijpharm.2013.11.044.
    • Niehoff A.-C., Moosmann A., Söbbing J., Wiehe A., Mulac D., Wehe C.A., Reifschneider O., Blaske F., Wagner S., Sperling M., von Briesen H., Langer K., Karst U. . ‘A palladium label to monitor nanoparticle-assisted drug delivery of a photosensitizer into tumor spheroids by elemental bioimaging.’ Metallomics 6, Nr. 1: 77-81. doi: 10.1039/c3mt00223c.
    • Meister S., Zlatev I., Stab J., Docter D., Baches S., Stauber R.H., Deutsch M., Schmidt R., Ropele S., Windisch M., Langer K., Wagner S., Von Briesen H., Weggen S., Pietrzik C.U. . ‘Nanoparticulate flurbiprofen reduces amyloid-β42 generation in an in vitro blood-brain barrier model.’ Alzheimer's Research and Therapy 5, Nr. 6. doi: 10.1186/alzrt225.
    • Storp B., Engel A., Böker A., Plöger M., Langer K. . ‘Albumin nanoparticles with predictable size by desolvation procedure.’ Journal of microencapsulation 29, Nr. 2: 138-46. doi: 10.3109/02652048.2011.635218.
    • Preuß A., Chen K., Hackbarth S., Wacker M., Langer K., Röder B. . ‘Photosensitizer loaded HSA nanoparticles II: In vitro investigations.’ International Journal of Pharmaceutics 404, Nr. 1-2: 308-316. doi: 10.1016/j.ijpharm.2010.11.023.
    • Löw K., Knobloch T., Wagner S., Wiehe A., Engel A., Langer K., von Briesen H. . ‘Comparison of intracellular accumulation and cytotoxicity of free mTHPC and mTHPC-loaded PLGA nanoparticles in human colon carcinoma cells.’ Nanotechnology 22, Nr. 24: 245102. doi: 10.1088/0957-4484/22/24/245102.
    • Löw K., Wacker M., Wagner S., Langer K., von Briesen H. . ‘Targeted human serum albumin nanoparticles for specific uptake in EGFR-Expressing colon carcinoma cells.’ Nanomedicine: nanotechnology, biology, and medicine 7. doi: 10.1016/j.nano.2010.12.003.
    • Chen K., Wacker M., Hackbarth S., Ludwig C., Langer K., Röder B. . ‘Photophysical evaluation of mTHPC-loaded HSA nanoparticles as novel PDT delivery systems.’ Journal of photochemistry and photobiology. B, Biology 101, Nr. 3: 340-7. doi: 10.1016/j.jphotobiol.2010.08.006.
    • Preuß A., Hackbarth S., Wacker M., Knobloch T., Langer K., Röder B. . ‘Comprehensive in vitro investigations on biodegradable photosensitizer-nanoparticle delivery systems.’ Journal of controlled release : official journal of the Controlled Release Society 148, Nr. 1: e117-e118. doi: 10.1016/j.jconrel.2010.07.089.
    • Preuß A., Chen K., Hackbarth S., Wacker M., Langer K., Röder B. . ‘Photosensitizer loaded HSA nanoparticles II: In vitro investigations.’ International journal of pharmaceutics 404: 308-316. doi: 10.1016/j.ijpharm.2010.11.023.
    • Wacker M., Chen K., Preuss A., Possemeyer K., Röder B., Langer K. . ‘Photosensitizer loaded HSA nanoparticles. I: Preparation and photophysical properties.’ International journal of pharmaceutics 393, Nr. 1-2: 253-62. doi: 10.1016/j.ijpharm.2010.04.022.
    • Wagner S., Rothweiler F., Anhorn M.G., Sauer D., Riemann I., Weiss E.C., Katsen-Globa A., Michaelis M., Cinatl J., Schwartz D., Kreuter J., von Briesen H., Langer K. . ‘Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles.’ Biomaterials 31, Nr. 8: 2388-98. doi: 10.1016/j.biomaterials.2009.11.093.
    • Geiler J., Michaelis M., Naczk P., Leutz A., Langer K., Doerr H.W., Cinatl J. . ‘N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus.’ BIOCHEMICAL PHARMACOLOGY 79, Nr. 3: 413-420. doi: 10.1016/j.bcp.2009.08.025.
    • Steinhauser I., Langer K., Strebhardt K., Spänkuch B. . ‘Uptake of plasmid-loaded nanoparticles in breast cancer cells and effect on Plk1 expression.’ Journal of drug targeting 17, Nr. 8: 627-37. doi: 10.1080/10611860903118823.
    • Chen K., Preuss A., Hackbarth S., Wacker M., Langer K., Röder B. . ‘Novel photosensitizer-protein nanoparticles for photodynamic therapy: photophysical characterization and in vitro investigations.’ Journal of photochemistry and photobiology. B, Biology 96, Nr. 1: 66-74. doi: 10.1016/j.jphotobiol.2009.04.006.
    • Holzer M., Vogel V., Mäntele W., Schwartz D., Haase W., Langer K. . ‘Physico-chemical characterisation of PLGA nanoparticles after freeze-drying and storage.’ European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V 72, Nr. 2: 428-37.
    • Müller R.S., Langer K. . „Nanotechnologie: Nanopartikel bringen Arzneistoffe sicher ans Ziel.“ Pharmazeutische Zeitung 4.
    • Anhorn M.G., Wagner S., Kreuter J., Langer K., von Briesen H. . ‘Specific Targeting of HER2 Overexpressing Breast Cancer Cells with Doxorubicin-Loaded Trastuzumab-Modified Human Serum Albumin Nanoparticles.’ Bioconjugate Chemistry 19, Nr. 12: 2321-2331. doi: 10.1021/bc8002452.
    • Anhorn M.G., Mahler H.C., Langer K. . ‘Freeze drying of human serum albumin (HSA) nanoparticles with different excipients.’ International journal of pharmaceutics 363, Nr. 1-2: 162-9. doi: 10.1016/j.ijpharm.2008.07.004.
    • Steinhauser I.M., Langer K., Strebhardt K.M., Spänkuch B. . ‘Effect of trastuzumab-modified antisense oligonucleotide-loaded human serum albumin nanoparticles prepared by heat denaturation.’ Biomaterials 29, Nr. 29: 4022-8. doi: 10.1016/j.biomaterials.2008.07.001.
    • Michaelis M., Bliss J., Arnold S.C., Hinsch N., Rothweiler F., Deubzer H.E., Witt O., Langer K., Doerr H.W., Wels W.S., Cinatl J. . ‘Cisplatin-Resistant Neuroblastoma Cells Express Enhanced Levels of Epidermal Growth Factor Receptor (EGFR) and Are Sensitive to Treatment with EGFR-Specific Toxins.’ CLINICAL CANCER RESEARCH 14, Nr. 20: 6531-6537. doi: 10.1158/1078-0432.CCR-08-0821.
    • Spänkuch B., Steinhauser I., Wartlick H., Kurunci-Csacsko E., Strebhardt K.I., Langer K. . ‘Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles.’ Neoplasia (New York, N.Y.) 10, Nr. 3: 223-34. doi: 10.1593/neo.07916.
    • Langer K., Anhorn M.G., Steinhauser I., Dreis S., Celebi D., Schrickel N., Faust S., Vogel V. . ‘Human serum albumin (HSA) nanoparticles: reproducibility of preparation process and kinetics of enzymatic degradation.’ International journal of pharmaceutics 347, Nr. 1-2: 109-17. doi: 10.1016/j.ijpharm.2007.06.028.
    • Dreis S., Rothweiler F., Michaelis M., Cinatl J., Kreuter J., Langer K. . ‘Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles.’ International journal of pharmaceutics 341, Nr. 1-2: 207-14. doi: 10.1016/j.ijpharm.2007.03.036.
    • Pereverzeva E., Treschalin I., Bodyagin D., Maksimenko O., Langer K., Dreis S., Asmussen B., Kreuter J., Gelperina S. . ‘Influence of the formulation on the tolerance profile of nanoparticle-bound doxorubicin in healthy rats: focus on cardio- and testicular toxicity.’ International journal of pharmaceutics 337, Nr. 1-2: 346-56. doi: 10.1016/j.ijpharm.2007.01.031.
    • Kreuter J., Hekmatara T., Dreis S., Vogel T., Gelperina S., Langer K. . ‘Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain.’ Journal of controlled release : official journal of the Controlled Release Society 118, Nr. 1: 54-8. doi: 10.1016/j.jconrel.2006.12.012.
    • Steinhauser I., Spänkuch B., Strebhardt K., Langer K. . ‘Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells.’ Biomaterials 27, Nr. 28: 4975-83. doi: 10.1016/j.biomaterials.2006.05.016.
    • Michaelis K., Hoffmann M.M., Dreis S., Herbert E., Alyautdin R.N., Michaelis M., Kreuter J., Langer K. . ‘Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain.’ The Journal of pharmacology and experimental therapeutics 317, Nr. 3: 1246-53. doi: 10.1124/jpet.105.097139.
    • Dinauer N., Balthasar S., Weber C., Kreuter J., Langer K., von Briesen H. . ‘Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes.’ Biomaterials 26, Nr. 29: 5898-906. doi: 10.1016/j.biomaterials.2005.02.038.
    • Balthasar S., Michaelis K., Dinauer N., von Briesen H., Kreuter J., Langer K. . ‘Preparation and characterisation of antibody modified gelatin nanoparticles as drug carrier system for uptake in lymphocytes.’ Biomaterials 26, Nr. 15: 2723-32. doi: 10.1016/j.biomaterials.2004.07.047.
    • Wartlick H., Michaelis K., Balthasar S., Strebhardt K., Kreuter J., Langer K. . ‘Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells.’ Journal of drug targeting 12, Nr. 7: 461-71. doi: 10.1080/10611860400010697.
    • Michaelis M., Langer K., Arnold S., Doerr H.W., Kreuter J., Cinatl J. . ‘Pharmacological activity of DTPA linked to protein-based drug carrier systems.’ Biochemical and biophysical research communications 323, Nr. 4: 1236-40. doi: 10.1016/j.bbrc.2004.08.223.
    • Brzoska M., Langer K., Coester C., Loitsch S., Wagner T.O., Mallinckrodt C. . ‘Incorporation of biodegradable nanoparticles into human airway epithelium cells-in vitro study of the suitability as a vehicle for drug or gene delivery in pulmonary diseases.’ Biochemical and biophysical research communications 318, Nr. 2: 562-70. doi: 10.1016/j.bbrc.2004.04.067.
    • Brzoska M., Langer K., Coester C., Loitsch S., Wagner T.O.F., Mallinckrodt C.V. . ‘Incorporation of biodegradable nanoparticles into human airway epithelium cells - in vitro study of the suitability as a vehicle for drug or gene delivery in pulmonary diseases.’ BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 318, Nr. 2: 562-570. doi: 10.1016/j.bbrc.2004.04.067.
    • Wartlick H., Spänkuch-Schmitt B., Strebhardt K., Kreuter J., Langer K. . ‘Tumour cell delivery of antisense oligonucleotides by human serum albumin nanoparticles.’ JOURNAL OF CONTROLLED RELEASE 96, Nr. 3: 483-495. doi: 10.1016/j.jconrel.2004.01.029.
    • Wartlick H., Spänkuch-Schmitt B., Strebhardt K., Kreuter J., Langer K. . ‘Tumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles.’ Journal of controlled release : official journal of the Controlled Release Society 96, Nr. 3: 483-95. doi: 10.1016/j.jconrel.2004.01.029.
    • Rhaese S., von Briesen H., Rübsamen-Waigmann H., Kreuter J., Langer K. . ‘Human serum albumin-polyethylenimine nanoparticles for gene delivery.’ Journal of controlled release : official journal of the Controlled Release Society 92, Nr. 1-2: 199-208.
    • Langer K., Balthasar S., Vogel V., Dinauer N., von Briesen H., Schubert D. . ‘Optimization of the preparation process for human serum albumin (HSA) nanoparticles.’ International journal of pharmaceutics 257, Nr. 1-2: 169-80. doi: 10.1016/S0378-5173(03)00134-0.
    • Michaelis M., Langer K., Vogel J.U., Kreuter J., Rabenau H., Doerr H.W., Cinatl J. . ‘In vitro antiviral activity of aphidicolin and its derivates - Synergistic effects of aphidicolin with other antiviral drugs.’ ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH 52, Nr. 5: 393-399.
    • Michaelis M., Cinatl J., Cinatl J., Pouckova P., Langer K., Kreuter J., Matousek J. . ‘Coupling of the antitumoral enzyme bovine seminal ribonuclease to polyethylene glycol chains increases its systemic efficacy in mice.’ ANTI-CANCER DRUGS 13, Nr. 2: 149-154. doi: 10.1097/00001813-200202000-00006.
    • Weber C., Reiss S., Langer K. . ‘Preparation of surface modified protein nanoparticles by introduction of sulfhydryl groups.’ International journal of pharmaceutics 211, Nr. 1-2: 67-78. doi: 10.1016/S0378-5173(00)00590-1.
    • Michaelis M., Vogel J.U., Cinati J., Langer K., Kreuter J., Schwabe D., Driever P.H., Cinati J. . ‘Cytotoxicity of aphidicolin and its derivatives against neuroblastoma cells in vitro: synergism with doxorubicin and vincristine.’ ANTI-CANCER DRUGS 11, Nr. 6: 479-485. doi: 10.1097/00001813-200007000-00009.
    • Michaelis M., Matousek J., Vogel J.U., Slavik T., Langer K., Cinatl J., Kreuter J., Schwabe D., Cinatl J. . ‘Bovine seminal ribonuclease attached to nanoparticles made of polylactic acid kills leukemia and lymphoma cell lines in vitro.’ Anti-cancer drugs 11, Nr. 5: 369-76. doi: 10.1097/00001813-200006000-00007.
    • Langer K., Coester C., Weber C., von Briesen H., Kreuter J. . ‘Preparation of avidin-labeled protein nanoparticles as carriers for biotinylated peptide nucleic acid.’ European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V 49, Nr. 3: 303-7.
    • Coester C.J., Langer K., von Briesen H., Kreuter J. . ‘Gelatin nanoparticles by two step desolvation - a new preparation method, surface modifications and cell uptake.’ JOURNAL OF MICROENCAPSULATION 17, Nr. 2: 187-193.
    • Coester C.J., Langer K., von Briesen H., Kreuter J. . ‘Gelatin nanoparticles by two step desolvation--a new preparation method, surface modifications and cell uptake.’ Journal of microencapsulation 17, Nr. 2: 187-93. doi: 10.1080/026520400288427.
    • Coester C., Kreuter J., von Briesen H., Langer K. . ‘Preparation of avidin-labelled gelatin nanoparticles as carriers for biotinylated peptide nucleic acid (PNA).’ International journal of pharmaceutics 196, Nr. 2: 147-9. doi: 10.1016/S0378-5173(99)00409-3.
    • Weber C., Kreuter J., Langer K. . ‘Desolvation process and surface characteristics of HSA-nanoparticles.’ International journal of pharmaceutics 196, Nr. 2: 197-200. doi: 10.1016/S0378-5173(99)00420-2.
    • Weber C., Coester C., Kreuter J., Langer K. . ‘Desolvation process and surface characterisation of protein nanoparticles.’ INTERNATIONAL JOURNAL OF PHARMACEUTICS 194, Nr. 1: 91-102. doi: 10.1016/S0378-5173(99)00370-1.
    • Weber C., Michaelis M., Vogel J.U., Cinatl J., Kreuter J., Langer K. . ‘Simple and efficient method for the detection of diethylenetriaminepentaacetic acid.’ JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND L 736, Nr. 1-2: 299-303. doi: 10.1016/S0378-4347(99)00456-9.
    • Aliautdin R.N., Petrov V.E., Langer K., Berthold A., Kreuter J., Kharkevich D.A. . ‘The delivery of loperamide to the brain by using polybutyl cyanoacrylate nanoparticles | Dostavka loperamida v mozg s pomoshch'iu polibutiltsianoarilatnykh nanochastits.’ Eksperimental'naia i klinicheskaia farmakologiia 61, Nr. 1: 17-20.
    • Aliautdin R.N., Petrov V.E., Langer K., Berthold A., Kreuter J., Kharkevich D.A. . ‘[The delivery of loperamide to the brain by using polybutyl cyanoacrylate nanoparticles].’ Eksperimental'naia i klinicheskaia farmakologiia 61, Nr. 1: 17-20.
    • Langer K., Lambrecht G., Moser U., Mutschler E., Kreuter J. . ‘Quantitative colorimetric and gas chromatographic determination of arecaidine propargyl ester.’ Journal of Chromatography B: Biomedical Applications 692, Nr. 2: 345-350. doi: 10.1016/S0378-4347(96)00521-X.
    • Langer K., Mutschler E., Lambrecht G., Mayer D., Troschau G., Stieneker F., Kreuter J. . ‘Methylmethacrylate sulfopropylmethacrylate copolymer nanoparticles for drug delivery. Part III: Evaluation as drug delivery system for ophthalmic applications.’ International Journal of Pharmaceutics 158, Nr. 2: 219-231. doi: 10.1016/S0378-5173(97)00255-X.
    • Langer K., Stieneker F., Lambrecht G., Mutschler E., Kreuter J. . ‘Methylmethacrylate sulfopropylmethacrylate copolymer nanoparticles for drug delivery. Part II: Arecaidine propargyl ester and pilocarpine loading and in vitro release.’ International Journal of Pharmaceutics 158, Nr. 2: 211-217. doi: 10.1016/S0378-5173(97)00256-1.
    • Langer K., Zimmer A., Kreuter J. . ‘Acrylic nanoparticles for ocular drug delivery.’ S.T.P. Pharma Sciences 7, Nr. 6: 445-451.
    • Alyautdin R.N., Petrov V.E., Langer K., Berthold A., Kharkevich D.A., Kreuter J. . ‘Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles.’ Pharmaceutical research 14, Nr. 3: 325-8. doi: 10.1023/A:1012098005098.
    • Pirker S., Kruse J., Noe C., Langer K., Zimmer A., Kreuter J. . ‘Characterization of polybutyleyanoacrylate nanoparticles. Part II: Determination of polymer content by NMR-analysis.’ International Journal of Pharmaceutics 128, Nr. 1-2: 189-195. doi: 10.1016/0378-5173(95)04305-5.
    • Langer K., Marburger C., Berthold A., Kreuter J., Stieneker F. . ‘Methylmethacrylate sulfopropylmethacrylate copolymer nanoparticles for drug delivery. Part I: Preparation and physicochemical characterization.’ International Journal of Pharmaceutics 137, Nr. 1: 67-74. doi: 10.1016/0378-5173(96)89589-5.
    • Langer K., Seegmüller E., Zimmer A., Kreuter J. . ‘Characterisation of polybutylcyanoacrylate nanoparticles: I. Quantification of PBCA polymer and dextrans.’ International Journal of Pharmaceutics 110, Nr. 1: 21-27. doi: 10.1016/0378-5173(94)90371-9.

    Aufsätze (Konferenz)

    • Mesken J., Iltzsche A., Mulac D., Langer K. . ‘EB1 modified HSA nanoparticles as non-viral delivery vectors-Influence of peptide concentration on cell uptake.’ Contributed to the 7. NRW Nano-Konferenz, Münster, Germany. doi: 10.1016/j.matpr.2017.09.183.
    • Raudszus B., Partikel K., Mulac D., Langer K. . ‘Characterisation and cellular uptake of polysorbate 80-coated PLA nanoparticles.’ Contributed to the 7. NRW Nano-Konferenz, Münster, Germany. doi: 10.1016/j.matpr.2017.09.186.
    • Pieper S., Langer K. . ‘Doxorubicin-loaded PLGA nanoparticles - A systematic evaluation of preparation techniques and parameters.’ Contributed to the 7. NRW Nano-Konferenz, Münster, Germany. doi: 10.1016/j.matpr.2017.09.185.

    Buchbeiträge (Sammel- oder Herausgeberbände)

    • Langer K. . „Überblick über Messmethoden und deren physikalische Hintergründe: Submikron.“ In Partikel in der Pharmaproduktion, herausgegeben von Stieneker F., 67-96.
    • Langer K. . „Peptide nanoparticles.“ In Nanotechnologies for the Life Sciences, Vol. 2: Biological and Pharmaceutical Nanomaterials, herausgegeben von Kumar C., 145-184.

    Kurzbeiträge (Poster)

    • Weitzel J., Langer K., Rose O. „Effects of generic exchange of levodopa: a pharmacy practice and biopharmaceutical approach.“ contributed to the ACCP Virtual Poster Symposium, online, .
    • Wünsch A., Mulac D., Langer K. „Nanoparticles inspired by lipoproteins: A lecithin stabilized and ApoE functionalized carrier system to overcome the blood-brain barrier.“ contributed to the DPhG Annual Meeting, Leipzig online, .
    • Wünsch A., Mulac D., Langer K. „ApoE-modified Lipid Nanoparticles Enclosing Different Core Variations to Overcome the Blood-Brain Barrier.“ contributed to the CRS Virtual Annual Meeting, online, .
    • Schoppa T., Mulac D., Rust T., Jung D., Kuckling D., Langer K. „New light-responsive polymeric nanoparticles as an on demand drug releasing system.“ contributed to the DPhG Annual Meeting, Leipzig online, .
    • Spreen H., Behrens M., Mulac D., Humpf H.U., Langer K. „Nanoparticle matrix and incubation medium – main influencer of the protein corona?“ contributed to the DPhG Annual Meeting, Leipzig online, .
    • Hester S., Ferenz K.B., Langer K. „Human serum albumin nanocapsules with a triglyceride core as a new nanocarrier system for lipophilic drugs.“ contributed to the DPhG Annual Meeting, Leipzig online, .
    • Spreen H., Barth C., Keuter L., Behrens M., Humpf H.U., Langer K. „Studies on the formation of a protein corona on colloidal drug carriers.“ contributed to the EMBO practical course – targeted proteomics: Experimental design and data analysis., CRG – Centre de Regulació Genòmica, online, .
    • Wünsch A., Mulac D., Langer K. „Imitating lipoproteins as drug delivery system - Apolipoprotein E-modified lipid nanoparticles.“ contributed to the 21. Bad Herrenalber Transporter-Tage, Bad Herrenalb, Germany, .
    • Wünsch A., Mulac D., Langer K. „Lipoprotein mimicking nanoparticles as colloidal drug delivery system.“ contributed to the DPhG Annual Meeting, Heidelberg, Germany, .
    • Alberding G., Mulac D., Langer K. „Surface modification of PLGA nanoparticles with cysteine for oral drug delivery.“ contributed to the DPhG Annual Meeting, Heidelberg, Germany, .
    • Barth C., Mulac D., Langer K. „Influence of PEG spacer selection on active targeting of trastuzumab-modified nanoparticles.“ contributed to the DPhG Annual Meeting, Heidelberg, Germany, .
    • Backhaus S., Mulac D., Langer K. „Are PLGA-based glutathione-modified nanoparticles sufficient to cross the blood-brain barrier?“ contributed to the 21. Bad Herrenalber Transporter-Tage, Bad Herrenalb, Germany, .
    • Alberding G., Mulac D., Langer K. „PLGA nanoparticles for oral drug delivery: Influence of polymer end groups and particle size on permeability in the Caco-2 model.“ contributed to the 21. Bad Herrenalber Transporter-Tage, Bad Herrenalb, Germany, .
    • Backhaus S., Mulac D., Langer K. „Preparation and characterization of penetratin-modified PLGA nanoparticles for endothelial cellular uptake.“ contributed to the 3rd European Conference on Pharmaceutics – Bringing science into pharmaceutical practice, Bologna, Italy, .
    • Grothe S., Langer K. „Eudragit® RL nanoparticles: Correlation between drug load and glass transition temperature.“ contributed to the 3rd European Conference on Pharmaceutics – Bringing science into pharmaceutical practice, Bologna, Italy, .
    • Hortmann P., Langer K., Bruns C. „Development of coated extract pellets using extrusion and spheronization.“ contributed to the 3rd European Conference on Pharmaceutics – Bringing science into pharmaceutical practice, Bologna, Italy, .
    • Neufeld N., Mulac D., Langer K. „Investigation of genipin as a bioalternative crosslinker for plasmid-loaded HSA nanoparticles.“ contributed to the 3rd European Conference on Pharmaceutics – Bringing science into pharmaceutical practice, Bologna, Italy, .
    • Sahnen F., Kamps J.P., Langer K. „Transformation of indomethacin nanosuspensions into tablets.“ contributed to the 3rd European Conference on Pharmaceutics – Bringing science into pharmaceutical practice, Bologna, Italy, .
    • Keuth J., Nitschke Y., Mulac D., Riehemann K., Rutsch F., Langer K. „Reversion of arterial calcification by elastin targeted nanoparticles.“ contributed to the 8th NRW Nano-Conference, Dortmund, Deutschland, .
    • Kimani N.M., Backhaus S., Matasyoh J.C., Kaiser M., Brun R., Langer K., Schmidt T.J. „PLA nanoparticles loaded with antitrypanosomal sesquiterpene lactones.“ contributed to the 8th NRW Nano-Conference, Dortmund, Deutschland, .
    • Neufeld N., Mulac D., Langer K. „Genipin crosslinked HSA nanoparticles for gene therapy: Impact of the crosslinker on transfection efficiency.“ contributed to the 8th NRW Nano-Conference, Dortmund, Deutschland, .
    • Partikel K., Mulac D., Langer K. „The time-dependent nanoparticle-protein corona.“ contributed to the 8th NRW Nano-Conference, Dortmund, Deutschland, .
    • Sahnen F., Langer K. „Development, characterization, and drying of indomethacin nanosuspensions prepared by wet media milling.“ contributed to the 8th NRW Nano-Conference, Dortmund, Deutschland, .
    • Stein N.C., Mulac D., Hermann F.C., Langer K. „Preparation and characterization of protein-stabilized mTHPC nanosuspensions.“ contributed to the 8th NRW Nano-Conference, Dortmund, Deutschland, .
    • Wünsch A., Mulac D., Langer K. „New lipid nanoparticle system based on lipoproteins: Cholesteryl oleate as solid core with different coatings.“ contributed to the NRW Nano-Conference, Dortmund, Deutschland, .
    • Grothe S., Langer K. „Eudragit® RS nanoparticles: Correlation between glass transition temperature and drug release.“ contributed to the 8th NRW Nano-Conference, Dortmund, Deutschland, .
    • Backhaus S., Mulac D., Langer K. „Improved cellular uptake of different polysorbate 80-coated PLGA nanoparticles.“ contributed to the 8th NRW Nano-Conference, Dortmund, Deutschland, .
    • Anderski J., Mahlert L., Mulac D., Sun J., Birnbaum W., Kuckling D., Langer K. „Light-sensitive nanoparticles as innovative drug delivery systems for a controlled drug release.“ contributed to the 11th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Granada, Spanien, .
    • Partikel K., Mulac D., Langer K. „Compositional evolution of the nanoparticle-protein corona with increasing concentration of human serum.“ contributed to the 11th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Granada, Spanien, .
    • Mahlert L., Anderski J., Mulac D., Langer K. „Overcoming the mucus barrier - in vitro evaluation of mucus permeating nanoparticles for PDT.“ contributed to the 11th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Granada, Spanien, .
    • Stein N.C., Mulac D., Herrmann F.C., Langer K. „Nanoparticle albumin-bound technology – Drug properties as a crucial aspect for an application.“ contributed to the DPhG Annual Meeting 2018, Hamburg, Deutschland, .
    • Frank K., Look J., Kiehm K., Langer K. „Mucoadhesive granules based on PLGA nanoparticles.“ contributed to the 11th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Granada, Spanien, .
    • Frank K., Look J., Cordts E., Langer K. „Mucoadhesive granulation and compression of nanoparticles.“ contributed to the DPhG Annual Meeting 2018, Hamburg, Deutschland, .
    • Wünsch A., Mulac D., Langer K. „Formation of colloidal particles by dialysis of mixed albumin solution with lecithin emulsion: Incompatibility or chance for a new lipid-based drug delivery system?“ contributed to the DPhG Annual Meeting 2018, Hamburg, Deutschland, .
    • Alberding G., Mulac D., Langer K. „PLGA nanoparticles for oral drug delivery: Know your basics to overcome the hurdles.“ contributed to the 8th NRW Nano-Conference, Dortmund, Deutschland, .
    • Anderski J., Mahlert L., Mulac D., Langer K. „Promising nanoparticulate drug delivery systems based on light-cleavable polymers.“ contributed to the 8th NRW Nano-Conference, Dortmund, Deutschland, .
    • Frank K., Look J., Kiehm K., Langer K. „Screening of polymers for a solid dosage form with mucoadhesion in the small intestine.“ contributed to the DPhG Annual Meeting, Saarbrücken, Germany, .
    • Sahnen F., Langer K. „Preparation and characterization of indomethacin nanosuspensions prepared by high-pressure homogenization.“ contributed to the DPhG Annual Meeting, Saarbrücken, Germany, .
    • Grothe S., Langer K. „Investigating the preparation of Eudragit® RL and RS nanoparticles via a solvent displacement method.“ contributed to the DPhG Annual Meeting, Saarbrücken, Germany, .
    • Backhaus S., Mulac D., Langer K. „Different strategies for the formation of blood-brain barrier crossing PLGA nanoparticles.“ contributed to the DPhG Annual Meeting, Saarbrücken, Germany, .
    • Pieper S., Langer K. „Influence of the pH value on the incorporation of doxorubicin in PLGA nanoparticles.“ contributed to the 2nd European Conference on Pharmaceutics, Krakau, Polen, .
    • Anderski J., Mahlert L., Mulac D., Langer K. „Photosensitizer-loaded nanoparticles: Promising drug delivery systems for photodynamic therapy of intestinal cancer?“ contributed to the DPhG Annual Meeting, Saarbrücken, Germany, .
    • Keuth J., Mulac D., Langer K. „Challenges in development of EDTA-nanoparticles for therapy of calcification disorders.“ contributed to the DPhG Annual Meeting, Saarbrücken, Germany, .
    • Neufeld N., Mulac D., Langer K. „Genipin as a bioalternative crosslinker for the stabilization of HSA nanoparticles.“ contributed to the DPhG Annual Meeting, Saarbrücken, Germany, .
    • Partikel K., Korte R., Hoevelmann Y., Mulac D., Langer K. „Effect of different serum types on the formation of the nanoparticle-protein corona.“ contributed to the DPhG Annual Meeting, Saarbrücken, Germany, .
    • Anderski J., Mahlert L., Mulac D., Langer K. „PLGA-based nanoparticles for oral application of photosensitizers as photodynamic therapy to treat gastrointestinal cancer.“ contributed to the 7th NRW Nano-Conference, Münster, Germany, .
    • Pieper S., Langer K. „Doxorubicin-loaded PLGA nanoparticles – a systematic evaluation of preparation techniques and parameters.“ contributed to the 7th NRW Nano-Conference, Münster, Germany, .
    • Mesken J, Mulac D, Langer K. „Cell penetrating peptides as targeting ligands for nanoparticle based gene therapy – Influence on cellular uptake and transfection efficiency.“ contributed to the 7th NRW Nano-Conference, Münster, Germany, .
    • Bernhardt A, Sahnen F, Langer K. „Preparation and characterization of fenofibrate nanosuspensions.“ contributed to the 7th NRW Nano-Conference, Münster, Germany, .
    • Partikel K, Korte R, Mulac D, Langer K. „Effect of nanoparticle size on the protein corona: A comparison between 100 and 200 nm PLGA nanoparticles.“ contributed to the 7th NRW Nano-Conference, Münster, Germany, .
    • Raudszus B., Partikel K., Mulac D., Langer K. „Characterization and cellular uptake of polysorbate 80-coated PLA nanoparticles.“ contributed to the 7th NRW Nano-Conference, Münster, Germany, .
    • Wessels L., Langer K. „Nanocapsules: hard shell, powerful centre?“ contributed to the PBP World Meeting, Glasgow, UK, .
    • Thoma F., Langer K. „New perspective for therapeutical protein delivery: model-based lipoproteins as drug delivery system.“ contributed to the PBP World Meeting, Glasgow, UK, .
    • Bernhardt A., Langer K. „Investigating the preparation of fenofibrate nanosuspensions by emulsion evaporation method.“ contributed to the PBP World Meeting, Glasgow, UK, .
    • Mesken J., Mulac D., Langer K. „Non-viral gene therapy: Successful uptake and transfection efficiency by plasmid-loaded protein-nanoparticles modified with cell penetrating peptides.“ contributed to the PBP World Meeting, Glasgow, UK, .
    • Pieper S., Langer K. „Entrapment of doxorubicin in different nanoparticle systems - an overview.“ contributed to the DPhG Annual Meeting, Düsseldorf, Germany, .
    • Lappe S., Langer K. „Investigating the influence of glass transition temperature on the release behaviour of flurbiprofen- and mTHPP-loaded poly(D,L-lactic-co-glycolic acid) nanoparticles.“ contributed to the 1st European Conference on Pharmaceutics – Drug Delivery, Reims, France, .
    • Raudszus B., Langer K. „Vinyl sulfone-poly(vinyl alcohol)-stabilized PLA-nanoparticles as reactive particle system for various surface modifications.“ contributed to the DPhG Annual Meeting, Düsseldorf, Germany, .
    • Horster L., Bernhardt A., Krenzlin S., Kiehm K., Langer K. „Fluid bed granulation for the incorporation of polymeric nanoparticles into lactose granules.“ contributed to the 1st European Conference on Pharmaceutics – Drug Delivery, Reims, France, .
    • Mesken J., Langer K. „Polyarginine modified human serum albumin (HSA) nanoparticles for effective cell transfection.“ contributed to the DPhG Annual Meeting, Düsseldorf, Germany, .
    • Lappe S., Langer K. „The glass transition temperature as an underestimated parameter for drug release properties of polymer based nanoparticles.“ contributed to the DPhG Annual Meeting, Düsseldorf, Germany, .
    • Thoma F., Langer K. „Lipoproteins as new protein delivery system.“ contributed to the DPhG Annual Meeting, Düsseldorf, Germany, .
    • Gisbert Fenoy C., Raudszus B., Zlatev I., Nienberg C., Langer K., Jose J. „Screening of nanoparticles for drug-delivery across the blood-brain barrier using autodisplayed LRP1 IV-domain on E. coli.“ contributed to the DPhG Annual Meeting, Düsseldorf, Germany, .
    • Elfering S., Langer K., Wünsch B. „Development of pH-responsive human serum albumin (HSA) nanoparticles: a possible new tool for cancer therapy.“ contributed to the 1st Joint European conference on therapeutic targets and medicinal chemistry (TTMC 2015), Münster, Germany, .
    • Gossmann R., Hummel M., Mulac D., Brockmeyer J., Langer K. „Cationic nanoparticles. An analytical approach to biological relevance.“ contributed to the 1st European Conference on Pharmaceutics – Drug Delivery, Reims, France, .
    • Gossmann R., Mulac D., Hummel M., Brockmeyer J., Langer K. „Cationic nanoparticles as a promising drug delivery system? In detail characterization of surface properties.“ contributed to the DPhG Annual Meeting, Frankfurt a.M., Germany, .
    • Lappe, S., Langer, K. „Glass transition temperature of poly(D,L-lactic-co-glycolic acid) nanoparticles.“ contributed to the DPhG Annual Meeting, Frankfurt a.M., Germany, .
    • Look J., Wilhelm N., Gorjup E., von Briesen H., Noske N., Rodriguez J.R., Prosper F., Serra M., Carrondo M., Alves P., Langer K. „Nanoparticles for gene delivery.“ contributed to the DPhG Annual Meeting, Frankfurt a.M., Germany, .
    • Thoma F., Langer K. „Strategies to improve colloidal stability of lysozyme-loaded nanoparticles.“ contributed to the DPhG Annual Meeting, Frankfurt a.M., Germany, .
    • Spek S., Häuser M., Schäfer M., Langer K. „Characterisation of PEGylated nanoparticles comparing the nanoparticle bulk to the particle surface using UV-Vis spectroscopy, SEC, 1H NMR spectroscopy and X-ray photoelectron spectroscopy.“ contributed to the DPhG Annual Meeting, Frankfurt a.M., Germany, .
    • Söbbing, J., Grünebaum, J., Mulac, D., Langer, K. „Are polymeric nanoparticles able to cross the gastrointestinal barrier?“ contributed to the DPhG Annual Meeting, Frankfurt a.M., Germany, .
    • Wessels, L., Tacke, S., Mulac, D., Langer, K. „Nanocapsules - Is the preparation of core-shell structured nanosystems that simple?“ contributed to the DPhG Annual Meeting, Frankfurt a.M., Germany, .
    • Herz T., John C., Langer K., Hempel G. „Development and validation of a new analytical method to characterize PEG-asparaginase by flow field-flow fractionation.“ contributed to the 35th EORTC-PAMM Winter Meeting, Münster, Germany, .
    • Gossmann R., Mulac D., Langer K. „New perspective in the formulation and characterization of DMAB-stabilized PLGA nanoparticles.“ contributed to the Internat. Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Lissabon, Portugal, .
    • John C., Langer K. „Asymmetrical flow field-flow fractionation in combination with inline-coupled dynamic light scattering techniques for analysis of PEGylation of protein nanoparticles.“ contributed to the Internat. Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Lissabon, Portugal, .
    • Spek S., Häuser M., Langer K. „Quantification of residual polyvinyl alcohol and poly (ethylene glycol) in PLGA nanoparticles by SEC, 1H-NMR and UV/VIS spectroscopy.“ contributed to the Internat. Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Lissabon, Portugal, .
    • Zlatev I., Langer K. „Protein modified PLA nanoparticles for active targeting.“ contributed to the Internat. Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Lissabon, Portugal, .
    • Krenzlin S., Wieland G., Langer K., Wagner S., Frankenfeld K., Anczykowski B., Spallek M. „Innovation in PDT: Oral administration of photosensitizers in treatment of cholangiocellular carcinoma.“ contributed to the Internat. Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Lissabon, Portugal, .
    • Mulac D., Fahrländer E., Gossmann R., Langer K. „Comparative examination of adsorption of serum proteins on HSA and PLGA based nanoparticles.“ contributed to the Internat. Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Lissabon, Portugal, .
    • Fahrländer E., Langer K. „PEGylated human serum albumin (HSA) nanoparticles: Preparation, characterisation and quantification of the PEGylation extent.“ contributed to the Internat. Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Lissabon, Portugal, .
    • Moosmann A., Klein J.-C., Kurz C., Knoll T., Söbbing J., Wieland G., Langer K., von Briesen H., Wagner S. „Transport of nanoparticles across the intestinal barrier.“ contributed to the Internat. Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Lissabon, Portugal, .
    • Grünebaum J., Söbbing J., Mulac D., Langer K. „Improved photocytotoxicity in cholangiocelullar carcinoma cell lines with mTHPP-loaded PLGA nanoparticles.“ contributed to the Internat. Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Lissabon, Portugal, .
    • Stab J., Zlatev I., Meister S., Langer K., Wronski R., Windisch M., Ropele S., Schmidt R., Deutsch M., Pietrzik C., von Briesen H., Wagner S. „Painkillers for Alzheimer’s disease – A nanoparticle-based approach to transport flurbiprofen to the brain.“ contributed to the Internat. Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Lissabon, Portugal, .
    • Söbbing J., Mulac D., Wieland G., Wiehe A., Langer K. „Preparation and physico-chemical evaluation of PLGA-nanoparticles for photodynamic tumor therapy.“ contributed to the Internat. Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Lissabon, Portugal, .
    • Wessels L., Hoffmann M., Weber F., Düfer M. Hempel G., Hensel A., Jose J., Langer K., Lehr M., Müller K., Schmidt T.J., Wünsch B. „PharMSchool.“ contributed to the DPhG Annual Meeting, Freiburg, Germany, .
    • Fahrländer E., Langer K. „Characterisation of PEGylated human serum albumin (HSA) as raw material for nanoparticle preparation.“ contributed to the DPhG Annual Meeting, Freiburg, Germany, .
    • John C., Langer K. „Asymmetrical flow field-flow fractionation (AF4) with inline-coupled dynamic light-scattering techniques for a deeper insight into nanoparticle formation.“ contributed to the DPhG Annual Meeting, Freiburg, Germany, .
    • Oppenberg J., Wilhelm N., Gorjup E., von Briesen H., Noske N., Huss R., Rodriguez J.R., Prosper F., Serra M., Carrondo M., Alves P., Langer K. „Generation and manipulation of stem cells by a nanoparticle mediated gene delivery system.“ contributed to the DPhG Annual Meeting, Freiburg, Germany, .
    • Kohl Y., Spek S., Hally F., Spallek M.J., Gonnissen D., Gribbon P., Wieland G.D., Wiehe A., Klein T., Riehemann K., von Briesen H., Langer K., Wagner S. „Biopolymer nanoparticles for therapeutic applications: Synthesis, characterization and assessment of biocompatibility.“ contributed to the NanoSafety, Saarbrücken, Germany, .
    • Söbbing J., Grünebaum J., Mulac D., Wieland G., Wiehe A., Langer K. „Preparation and biological evaluation of mTHPP-loaded PLGA nanoparticles for photodynamic tumor therapy.“ contributed to the DPhG Annual Meeting, Freiburg, Germany, .
    • Stab J., Zlatev I., Meister S., Langer K., Wronski R., Windisch M., Ropele S., Schmidt R., Deutsch M., Pietrzik C., von Briesen H., Wagner S. „Making transport possible: Flurbiprofen-loaded nanoparticles for the treatment of Alzheimer´s disease.“ contributed to the 15. Bad Herrenalber Transporter-Tage, Bad Herrenalb, Germany, .
    • Fahrländer E., Langer K. „PEGylated human serum albumin (HSA) nanoparticles: Preparation, characterisation and quantification of the PEGylation efficiency.“ contributed to the DPhG Annual Meeting, Freiburg, Germany, .
    • Böker A., Langer K. „Native and reversible protein precipitation for the preparation of nanoparticles.“ contributed to the Internat. Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Istanbul, Turkey, .
    • Wilhelm N., Oppenberg J., Langer K., Rodriguez J.R., Prosper F., Serra M., Carrondo M., Alves P., Noske N., Kern S., Huss R., Günther C., von Briesen H., Gorjup E. „Generation and manipulation of stem cells by a nanoparticle mediated gene delivery system.“ contributed to the EMBL Conference: Stem cells in cancer and regenerative medicine, Heidelberg, Germany, .
    • Häuser M., Langer K., Schönhoff M. „pH-triggered polyelectrolyte desorption from electrostatically surface modified poly(lactic-co-glycolic acid) nanoparticles.“ contributed to the 26th Conference of the European Colloid and Interface Society, Malmö, Sweden, .
    • Häuser M., Langer K., Schönhoff M. „pH-triggered polyelectrolyte desorption from electrostatically surface modified poly(lactic-co-glycolic acid) nanoparticles.“ contributed to the 8. Zsigmondy-Kolloquium der Kolloidgesellschaft, Darmstadt, Germany, .
    • Häuser M., Langer K., Schönhoff M. „Investigation of the adsorption of polyarylic acid onto surface modifed poly(lactic-co-glycolic acid) nanoparticles.“ contributed to the 7. Zsigmondy-Kolloquium der Kolloidgesellschaft, Münster, Germany, .
    • Wacker M., Preuss A., Chen K., Röder B., Langer K. „Photosensitizer loaded HSA nanopartcles – Preparation process and cellular uptake.“ contributed to the GPEN Meeting, Chapel Hill NC, USA, .
    • Preuß A., Hackbarth S., Wacker M., Knobloch T., Langer K., Röder B. „Comprehensive in vitro investigations on biodegradable photosensitizer-nanoparticle delivery systems.“ contributed to the 8th International Symposium on Photodynamic Therapy and Photodiagnosis in Clinical Practice, Brixen, Italy, .
    • Wacker M., Preuss A., Chen K., Roeder B., Langer K. „Photosensitizer loaded HSA nanoparticles: Optimization of the preparation process and uptake into Jurkat cells.“ contributed to the AAPS Annual Meeting and Exposition, New Orleans, USA, .
    • Löw K., Knobloch T., Wagner S., Wiehe A., Langer K., von Briesen H. „Cytotoxicity and intracellular accumulation of mTHPC and mTHPC-loaded PLGA-nanoparticles in colon carcinoma cells.“ contributed to the 8th International Symposium on Photodynamic Therapy and Photodiagnosis in Clinical Practice, Brixen, Italy, .
    • Preuss A., Hackbarth S., Wacker M., Knobloch T., Langer K., Röder B. „Comprehensive in vitro investigations on biodegradable photosensitizer-nanoparticle delivery systems.“ contributed to the European Symposium on Controlled Drug Delivery, Egmond aan Zee, Netherlands, .
    • Knobloch T., Langer K. „Antibody modified PLGA-nanoparticles: Introduction and quantification of amino groups.“ contributed to the Internat. Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Valetta, Malta, .
    • Engel A., Plöger M., von Storp B., Böker A., Langer K. „Preparation of albumin nanoparticles by desolvation - Evaluation of process parameters I.“ contributed to the Internat. Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Valetta, Malta, .
    • Plöger M., von Storp B., Böker A., Engel A., Langer K. „Preparation of albumin nanoparticles by desolvation - Evaluation of process parameters II.“ contributed to the Internat. Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Valetta, Malta, .
    • Löw K., Wacker M., Wagner S., Langer K., von Briesen H. „Accumulation of targeted HSA-nanoparticles in different colon carcinoma cell lines using EGFR-expression.“ contributed to the Internat. Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Valetta, Malta, .
    • Böker A., Engel A., Plöger M., von Storp B., Langer K. „Preparation of human serum albumin nanoparticles in the sub-100 nm size range.“ contributed to the DPhG Annual Meeting, Jena, Germany, .
    • Vogel V., Langer K., Mäntele W. „Fluorescence spectroscopy, fluorescence imaging and analytical ultracentrifugation in controlled drug release and drug imaging.“ contributed to the European Conference on the Spectroscopy of Biological Molecules, Palermo, Italy, .
    • Wagner S., Anhorn M.G., Kreuter J., Langer K., von Briesen H. „Specific targeting of cancer cells with doxorubicin-loaded nanoparticles.“ contributed to the 36th Annual Meeting & Exposition of the Controlled Release Society, Copenhagen, Denmark, .

  • Promotionen

    Barth, ChristinaZellspezifisches Targeting proteinbasierter Nanopartikel
    Neufeld, NellyNanopartikuläre DNA-Trägersysteme als alternative nicht-virale Gen-Vektoren
    Stein, NoraProteinstabilisierung nanopartikulärer Arzneiformen
    Sahnen, FredericÜberführung von Arzneistoff-Nanosuspensionen zu festen Arzneiformen.
    Backhaus, SolveigOberflächenmodifizierte PLGA-Nanopartikel zur Überwindung der Blut-Hirn-Schranke.
    Wünsch, AngelikaImitation von Lipoproteinen als nanopartikuläre Arzneistoffträgersysteme
    Alberding, GerritNanopartikuläre Arzneiformen zur Überwindung der gastrointestinalen Barriere.
    Frank, KatharinaMukoadhäsive Darreichungsformen zur nanopartikulären photodynamischen Tumortherapie
    Grothe, StephaniePhysikochemische Charakterisierung von Nanopartikeln auf Basis ausgewählter Eudragit®-Polymere
    Motealleh, AndishehSynthese nanokompositer Hydrogele und stereoselektive Zell-Interaktion.
    Keuth, JacquelineNanopartikuläre Arzneiformen zum Einsatz in der Therapie arterieller Calcifizierungen
    Partikel, KatrinUntersuchung der Proteinadsorption an PLGA-Nanopartikeln.
    Pieper, SebastianEntwicklung und Charakterisierung von Nanopartikeln zur Resistenzüberwindung von Tumorzellen
    Mahlert, LauraZellbiologische Bewertung Licht-responsiver Nanosysteme zur Anwendung in der intestinalen Tumortherapie.
    Anderski, JulianeEntwicklung Licht-responsiver Nanopartikel als Arzneistoffvehikel für die photodynamische Tumortherapie.
    Mesken, JuliaOberflächenmodifizierte HSA-Nanopartikel als nicht-virale DNA-Vektoren.
    Raudszus, BastianEntwicklung und biologische Testung oberflächenmodifizierter PLA-Nanopartikel zur Überwindung der Blut-Hirn-Schranke
    Eidam, SebastianStakeholdermanagement bei der kooperativen Entwicklung von Arzneimitteln
    Wessels, LisaNanokapseln - Herstellungsmethoden, Charakterisierung und in vitro-Untersuchungen
    Horster, LutzWirbelschichtgranulierung mit polymeren Nanopartikeln
    Thoma, FrederiqueEntwicklung und Charakterisierung kolloidaler Trägersysteme für Proteine
    Grünebaum, JonasIn vitro Charakterisierung von nanopartikulären Trägersystemen für die photodynamische Therapie
    Gossmann, RebeccaEntwicklung kationischer Nanopartikel und deren Zellinteraktion
    Fröhleke, Anna KatharinaMöglichkeiten und Grenzen von PK-Sim® in der pädiatrischen Onkologie am Beispiel der Anthrazykline
    Lappe, SvenjaGlasübergangstemperatur und Freisetzungsverhalten polymerer Nanopartikel
    Spek, SilviaEntwicklung und Charakterisierung nanopartikulärer Systeme zur Analyse von Partikel-Zell-Interaktionen
    Look, JenniferNeuartige Liganden-modifizierte Nanopartikel als Trägersysteme für Nukleinsäuren
    Fahrländer, Eva-MariaEntwicklung und Charakterisierung PEGylierter HSA-Nanopartikel
    Zlatev, IavorEntwicklung von Nanopartikeln als Träger für Alzheimer Therapeutika
    John, CorneliaAsymmetrische Fluss-Feldfluss-Fraktionierung zur Charakterisierung kolloidaler Systeme
    Hindel, StefanEntwicklung einer nanopartikulären Arzneimittelformulierung auf der Basis von PLGA zum aktiven Drug-Targeting von Doxorubicin an Tumorzellen mittels des monoklonalen Antikörpers DI17E6
    Häuser, ManuelEntwicklung pH-schaltbarer Nanopartikelsysteme zur intrazellulären Wirkstofffreisetzung
    Dickschen, Kristin Josefine RuthÜberwindung der CYP2D6 vermittelten Tamoxifenresistenz bei postmenopausalen Brustkrebs: ein PBPK-Ansatz
    von Storp, BernhardEntwicklung nanopartikulärer Arzneiformen für niedermolekulare Kinase-Inhibitoren zur Anwendung in der Tumortherapie
    Engel, AndreaNanopartikuläre Trägersysteme für Tetrapyrrole
    Plöger, MichaelEntwicklung nanopartikulärer Arzneiformen für biologisch aktive sekundäre Pflanzeninhaltsstoffe
    Böker, AnnePartikuläre Arzneiformen zur kontrollierten Proteinfreisetzung
    Klassert, DeniseAngiogenes Potential chemoresistenter und persistenter HCMV-infizierter Neuroblastomzellen
    Holzer, MelisandeAntikörperbeladene PLGA-Nanopartikel als Trägersystem für eine verzögerte Wirkstofffreisetzung in der Tumortherapie
    Geiler, JaninaUntersuchungen der Immunreaktion in Influenza-A-infizierten Zellen und Analyse von potentiellen antiviralen Substanzen
    Wacker, MatthiasEntwicklung zellspezifischer Arzneistoffträger zur Tumortherapie

  • Vorträge

    • Anderski, Juliane; Mahlert, Laura (): ‘Interactions of nanoparticles with mucus - the first barrier before reaching intestinal cells’. Bad Herrenalber Transporter- und Barrieretage, Bad Herrenalb, Deutschland, .

    • Raudszus, Bastian; Mulac, Dennis; Langer, Klaus (): ‘Apo E-modification of PLA-nanoparticles enhances cellular uptake into brain endothelium’. 10th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Glasgow, Vereinigtes Königreich, .

Vorlesung:

"Pharmazeutische Technologie einschließlich Medizinprodukte" für das 5., 6. und 7. Semester

"Biopharmazie einschl. arzneiformenbezogener Pharmakokinetik" für das 5., 6. und 7. Semester

 

Seminar:

"Qualitätssicherung bei Herstellung und Prüfung von Arzneimitteln"